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To the editor:Recently in Alzheimer’s and Dementia: Translational
Research and Clinical Interventions, Liu-Seifert et al. [1]
described the results of the EXPEDITION-EXT study, an
open-label extension of the randomized EXPEDITION and
EXPEDITION2 trials. Although the original trials assessed
the efficacy of solanezumab in patients with mild-to-
moderate Alzheimer’s disease (AD) [2], the open-label
extension was intended for safety-monitoring (https://
clinicaltrials.gov/ct2/show/NCT01127633). The authors im-
plemented certain modifications to the delayed-start analysis
[3], first proposed by Leber [4] in 1996 for differentiating
disease-modifying treatment effects from symptom relief,
and applied these to the EXPEDITION-EXT data. From
this, they conclude that their proposed modifications of the
delayed-start methodology are “appropriate for ascertaining
long-term effectiveness and possible disease-modifying ef-
fects of AD treatments.” Although the presented methodol-
ogy is interesting, we believe there are several limitations
to the method and analyses, which are insufficiently, if at
all, addressed in the article.
First, since its introduction in 1996, the delayed-start
method has rarely been applied in practice, in part, because
of uncertainty about how to determine the difference between
groups in the extension phase. Here, the authors use a nonin-
feriority approach. Even in case of perfect study attrition, this
approach suffers from much lower power than the original
trial because of comparison of two measured differences
with their separate variances. In fact, the power for their
model was estimated by the authors to be less than 50%
[3]. Moreover, it is arguable whether the chosen 50% nonin-
feriority margin (reflecting a 0.9-point gain on the 90-point
ADAS-Cog14 scale) qualifies as the “largest clinically
acceptable loss of treatment benefit” strived for. In compari-
son, acetylcholinesterase inhibitors cause an average 2.7-
point improvement on the 70-point ADAS-Cog scale [5],
and clinical benefits are generally considered marginal.*Corresponding author. Tel.: 131-642212944; Fax: 131-107044657.
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for several reasons. Of the original 1322 participants in
EXPEDITION and EXPEDITION2 with mild AD, only
975 (73.8%) were enrolled in the extension phase, of
whom 581 (43.9%) completed 2-year follow-up [1]. Equal
drop-out percentage in both treatment groups does not rule
out selection bias, when data are not missing completely at
random. Furthermore, even nondifferential misclassifica-
tion of outcome can introduce bias toward the 0. For the
delayed-start design, this means that nondifferential
misclassification suffices to have no converging of groups
in the extension phase, and, thus, falsely imply noninferior-
ity. Moreover, randomization at baseline does not prevent
post-randomization confounding and selection bias [6].
For instance, use of acetylcholinesterase inhibitors during
the study period may differ over time between groups,
which is not accounted for by adjusting for baseline use.
Third, concerning the analyses, the authors fit mixed
models to various time-points during follow-up and conclude
treatment differences persisted during “much of the delayed-
start period.” Although the treatment differences indeed per-
sisted up till a year, at the end of the 2-year follow-up period,
differences were no longer significant and the noninferiority
criteria for the primary outcomemeasures ADAS-Cog14 and
ADCS-iADLno longermet. In any case, assessing each time-
point separately is equivalent to performing (in this case 9)
interim analyses, for which correction of the P value
threshold for statistical significance should be made.
Finally, none of the brain imaging markers during the
EXPEDITION trials showed any difference in favor of treat-
ment with solanezumab [2]. As these were measured to
detect disease modification, discrepancy between estab-
lished biomarkers of disease progression and analytical
methods as the delayed-start design should be met with
caution. Before considering the delayed-start design as a
valid, stand-alone method for demonstrating disease modifi-
cation by a treatment, we believe validation on well-
established disease-modifying and symptomatic drugs for
other conditions than AD is warranted.
Since presentation and subsequent publication of the
delayed-start findings of the EXPEDITION trials [3], media
have reported this as a breakthrough in treatment for AD [7],
which has had its effects on the lay public, policy makers,
even stock markets, and other stakeholders. We hope to
have clarified here why this euphoria is at best premature.imer’s Association. This is an open access article under the CC BY-NC-ND
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